SAFETY AND EFFICACY OF 4 YEARS OF DEFERASIROX TREATMENT FOR SICKLE CELL DISEASE PATIENTS

被引：3

作者：

Vlachaki, Efthymia ^{[1
]}

Mainou, Maria ^{[2
]}

Bekiari, Eleni ^{[2
]}

Vetsiou, Evaggelia ^{[1
]}

Tsapas, Apostolos ^{[2
]}

机构：

[1] Aristotle Univ Thessaloniki, Hippokratio Gen Hosp, Thalassemia Unit, Dept Med 2, Thessaloniki 54642, Greece

[2] Aristotle Univ Thessaloniki, Metab Dis Unit, Dept Med 2, Thessaloniki 54642, Greece

来源：

HEMOGLOBIN | 2013年 / 37卷 / 01期

关键词：

Deferasirox (DFRA); Chelation treatment; Sickle cell disease; ORAL IRON CHELATOR; THERAPY; DEFERIPRONE; OVERLOAD; THALASSEMIA; MORBIDITY; MORTALITY;

D O I：

10.3109/03630269.2012.746696

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Deferasirox (DFRA) is a novel oral chelator agent for treatment of iron overload. Although well established in the treatment of beta-thalassemia major (beta-TM), it has not yet been fully investigated in patients with sickle cell disease. The aim of this report is to present the preliminary results of a pilot study assessing the effect of 4 years of DFRA treatment in six patients with sickle cell disease who are in need of recurrent transfusions. Our results show a significant reduction of ferritin levels and improvement of liver hemosiderosis, assessed by means of magnetic resonance imaging T2* (MRI T2*). None of the patients presented any serious adverse effects and the treatment was well tolerated. These results are in accordance with previous studies about the use of DFRA in sickle cell disease.

引用

页码：94 / 100

页数：7

共 26 条

[1] Fetal hemoglobin in sickle cell anemia
Akinsheye, Idowu
Alsultan, Abdulrahman
Solovieff, Nadia
Duyen Ngo
Baldwin, Clinton T.
Sebastiani, Paola
Chui, David H. K.
Steinberg, Martin H.
[J]. BLOOD, 2011, 118 (01) : 19 - 27
[2] Medical progress: Disorders of iron metabolism
Andrews, NC
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (26) : 1986 - 1995
[3] Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease
Ballas, SK
[J]. SEMINARS IN HEMATOLOGY, 2001, 38 (01) : 30 - 36
[4] A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β-thalassemia
Cappellini, MD
Cohen, A
Piga, A
Bejaoui, M
Perrone, S
Agaoglu, L
Aydinok, Y
Kattamis, A
Kilinc, Y
Porter, J
Capra, M
Galanello, R
Fattoum, S
Drelichman, G
Magnano, C
Verissimo, M
Athanassiou-Metaxa, M
Giardina, P
Kourakli-Symeonidis, A
Janka-Schaub, G
Coates, T
Vermylen, C
Olivieri, N
Thuret, I
Opitz, H
Ressayre-Djaffer, C
Marks, P
Alberti, D
[J]. BLOOD, 2006, 107 (09) : 3455 - 3462
[5] Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone
Cohen, AR
Galanello, R
Piga, A
De Sanctis, V
Tricta, F
[J]. BLOOD, 2003, 102 (05) : 1583 - 1587
[6] Cohen AR, 2000, BRIT J HAEMATOL, V108, P305
[7] New insights on pathophysiology, clinical manifestations, diagnosis, and treatment of sickle cell nephropathy
da Silva Junior, Geraldo Bezerra
Liborio, Alexandre Braga
Daher, Elizabeth De Francesco
[J]. ANNALS OF HEMATOLOGY, 2011, 90 (12) : 1371 - 1379
[8] Secondary Prevention of Overt Strokes in Sickle Cell Disease: Therapeutic Strategies and Efficacy
DeBaun, Michael R.
[J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2011, : 427 - 433
[9] Deferasirox-induced renal impairment in children: an increasing concern for pediatricians
Dubourg, Laurence
Laurain, Celine
Ranchin, Bruno
Pondarre, Corinne
Hadj-Aissa, Aoumeur
Sigaudo-Roussel, Dominique
Cochat, Pierre
[J]. PEDIATRIC NEPHROLOGY, 2012, 27 (11) : 2115 - 2122
[10] Morbidity and mortality in chronically transfused subjects with thalassemia and sickle cell disease: A report from the multi-center study of iron overload
Fung, Ellen B.
Harmatz, Paul
Milet, Meredith
Ballas, Samir K.
De Castro, Laura
Hagar, Ward
Owen, William
Olivieri, Nancy
Smith-Whitley, Kim
Darbari, Deepika
Wang, Winfred
Vichinsky, Elliott
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (04) : 255 - 265

← 1 2 3 →